(PRBuzz.com) April 5, 2013 -- Global Markets Direct's, 'Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections. Varicella Zoster (HHV-3) Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556279_varicella_zoster_hhv3_infections_pipeline_review.aspx?afid=101
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Varicella Zoster (HHV-3) Infections.
* A review of the Varicella Zoster (HHV-3) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Varicella Zoster (HHV-3) Infections pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Varicella Zoster (HHV-3) Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Varicella Zoster (HHV-3) Infections
Varicella Zoster (HHV-3) Infections Therapeutics under Development by Companies
Varicella Zoster (HHV-3) Infections Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Varicella Zoster (HHV-3) Infections Therapeutics - Products under Development by Companies
Varicella Zoster (HHV-3) Infections Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Varicella Zoster (HHV-3) Infections Therapeutics Development
GlaxoSmithKline plc
Merck & Co., Inc.
Isotechnika Pharma Inc.
Nutra Pharma Corporation
Panacea Biotec Limited
aRigen Pharmaceuticals, Inc.
Sinovac Biotech Ltd.
Epiphany Biosciences, Inc.
Synergy Pharmaceuticals, Inc.
China National Pharmaceutical Group Corporation
Varicella Zoster (HHV-3) Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
FV-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RPI-78M - Drug Profile
Product Description
Mechanism of Action
R&D Progress
valomaciclovir stearate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zoster - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Varicella-zoster vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-208136 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chickenpox Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-1437173A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NICAM Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sattabacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Varicella Live Attenuated Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Varicella Zoster (HHV-3) Infections Therapeutics - Drug Profile Updates
Varicella Zoster (HHV-3) Infections Therapeutics - Discontinued Products
Varicella Zoster (HHV-3) Infections Therapeutics - Dormant Products
Varicella Zoster (HHV-3) Infections - Product Development Milestones
Featured News & Press Releases
Jul 18, 2012: Agenus Annnounces Intiation Of Phase III Clinical Trial Of GSK's Herpes Zoster Vaccine Candidate In Immunocompromised Patients
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad
Feb 01, 2012: Asahi Kasei Pharma Files Application For Approval Of Famvir Anti-herpes Agent For Additional Indication

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=556279&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

(PRBuzz.com) April 5, 2013 -- Global Markets Direct's, 'Duchenne Muscular Dystrophy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy. Duchenne Muscular Dystrophy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556312_duchenne_muscular_dystrophy_pipeline_review_h1.aspx?afid=101
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Duchenne Muscular Dystrophy.
* A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Duchenne Muscular Dystrophy Overview
Therapeutics Development
An Overview of Pipeline Products for Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy Therapeutics under Development by Companies
Duchenne Muscular Dystrophy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Duchenne Muscular Dystrophy Therapeutics - Products under Development by Companies
Duchenne Muscular Dystrophy Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Duchenne Muscular Dystrophy Therapeutics Development
GlaxoSmithKline plc
AVI BioPharma Inc.
Galapagos NV
Summit Corporation plc
Santhera Pharmaceuticals Holding AG
Italfarmaco S.p.A.
Acceleron Pharma, Inc.
Catabasis Pharmaceuticals, Inc.
PTC Therapeutics, Inc.
Fate Therapeutics, Inc.
N-Gene Research Laboratories, Inc.
Asklepios BioPharmaceutical, Inc.
Genethon
Prosensa Therapeutics B.V.
Duchenne Muscular Dystrophy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ataluren - Drug Profile
ataluren - Drug Profile
SMT-C1100 - Drug Profile
ACE-031 - Drug Profile
eteplirsen - Drug Profile
Exon 50 PMO - Drug Profile
drisapersen - Drug Profile
GLPG-0492 - Drug Profile
AMT-080 - Drug Profile
Anti-Sense Exon-Skipping Therapy - Drug Profile
Biostrophin - Drug Profile
idebenone - Drug Profile
BGP-15 - Drug Profile
Epigallocatechin Gallate - Drug Profile
rAAV2.5-CMV - Drug Profile
ITF-2357 - Drug Profile
mecasermin rinfabate - Drug Profile
PRO-045 - Drug Profile
PRO-053 - Drug Profile
PRO-052 - Drug Profile
PRO-055 - Drug Profile
CRD-007 - Drug Profile
FT-301 - Drug Profile
Duchenne Muscular Dystrophy Program - Drug Profile
Drug For Duchenne Muscular Dystrophy - Drug Profile
LAM-111 - Drug Profile
PRT-300 - Drug Profile
PRT-20 - Drug Profile
VBP-15 - Drug Profile
RE-001 - Drug Profile
halofuginone hydrobromide - Drug Profile
S-107 - Drug Profile
CAT-1040 - Drug Profile
PRT-400 - Drug Profile
PRT-500 - Drug Profile
Wnt7a--Based Protein Thearpeutics - Drug Profile
RTC-13 - Drug Profile
Exon 45 PMO - Drug Profile
RTC-14 - Drug Profile
AAV5 Gene Therapy - Drug Profile
Utrophin - Drug Profile
ARM-210 - Drug Profile
Protein For Muscular Dystrophy - Drug Profile
Synthetic Mini Dystrophin Gene - Drug Profile
4s3-003 - Drug Profile
Duchenne Muscular Dystrophy Therapeutics - Drug Profile Updates
Duchenne Muscular Dystrophy Therapeutics - Dormant Products
Duchenne Muscular Dystrophy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=556312&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

(PRBuzz.com) April 5, 2013 -- Global Markets Direct's, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556315_chronic_kidney_disease_chronic_renal_failure.aspx?afid=101
------------------------------------------------------------

Scope

* A snapshot of the global therapeutic scenario for Chronic Kidney Disease (Chronic Renal Failure).
* A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Kidney Disease (Chronic Renal Failure) Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure)
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Products under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Development
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
Quark Pharmaceuticals, Inc.
FibroGen, Inc.
Astellas Pharma Inc.
Kureha Corporation
Bayer AG
Evotec Aktiengesellschaft
Nile Therapeutics, Inc.
La Jolla Pharmaceutical Company
Alexion Pharmaceuticals, Inc.
Dynavax Technologies Corporation
Pieris AG
Hawthorn Pharmaceuticals, Inc.
Promedior, Inc.
Catabasis Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc.
Angion Biomedica Corp.
Thrasos, Inc.
Concert Pharmaceuticals, Inc.
CorMedix, Inc.
Bolder Biotechnology, Inc.
Vitae Pharmaceuticals, Inc.
Stelic Institute & Co.
Ardelyx, Inc.
Sorbent Therapeutics, Inc.
Vicore Pharma AB
Cellmid Ltd
InVasc Therapeutics, Inc.
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
beraprost sodium - Drug Profile
tabalumab - Drug Profile
FG-3019 - Drug Profile
cinacalcet hydrochloride - Drug Profile
bardoxolone methyl - Drug Profile
PRS-080 - Drug Profile
eculizumab - Drug Profile
Hepatitis B Vaccine - Drug Profile
CU-NP - Drug Profile
AST-120 - Drug Profile
THR-123 - Drug Profile
siRNA For Chronic Diseases - Drug Profile
G Family Inhibitor For CKD - Drug Profile
VTP-27999 - Drug Profile
CLP-1004 - Drug Profile
atorvastatin calcium - Drug Profile
GCS-100 - Drug Profile
everolimus - Drug Profile
benazepril hydrochloride - Drug Profile
benazepril hydrochloride + valsartan - Drug Profile
Neo-Kidney Augment - Drug Profile
Neo-Kidney Augment - Drug Profile
deferiprone - Drug Profile
Haw Nuv-15 - Drug Profile
Haw Nuv-16 - Drug Profile
(losartan potassium + alpha lipoic acid) - Drug Profile
LY-2623091 - Drug Profile
Autograft Progenitor Of Hepatocyte Derived From Mesenchymal Stem Cell - Drug Profile
ZS-9 - Drug Profile
CTP-499 - Drug Profile
PRM-151 Subcutaneous - Drug Profile
RDX-5791 - Drug Profile
BBT-021 - Drug Profile
Compound-21 - Drug Profile
BAY-85-3934 - Drug Profile
ANG-3070 - Drug Profile

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=556315&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

(PRBuzz.com) April 5, 2013 -- Global Markets Direct's, 'Irritable Bowel Syndrome - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Irritable Bowel Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome. Irritable Bowel Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556319_irritable_bowel_syndrome_pipeline_review_h1_2013.aspx?afid=101
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Irritable Bowel Syndrome.
* A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Irritable Bowel Syndrome pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Irritable Bowel Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Irritable Bowel Syndrome
Irritable Bowel Syndrome Therapeutics under Development by Companies
Irritable Bowel Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Irritable Bowel Syndrome Therapeutics - Products under Development by Companies
Irritable Bowel Syndrome Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Irritable Bowel Syndrome Therapeutics Development
AstraZeneca PLC
Dainippon Sumitomo Pharma Co., Ltd.
Albany Molecular Research, Inc.
Astellas Pharma Inc.
Dong-A Pharmaceutical Co., Ltd.
Kureha Corporation
Ono Pharmaceutical Co., Ltd.
Menarini Group
Shire Plc
Pharmos Corporation
Lexicon Pharmaceuticals, Inc.
Yuhan Corporation
ProMetic Life Sciences Inc.
Probiomics Ltd.
Alba Therapeutics Corporation
Ironwood Pharmaceuticals, Inc.
Respiratorius AB
Tioga Pharmaceuticals, Inc.
Targacept, Inc.
Drais Pharmaceuticals, Inc.
Synergy Pharmaceuticals, Inc.
Napo Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc.
Alfa Wassermann S.p.A
MicroDose Therapeutx, Inc.
RaQualia Pharma Inc.
Irritable Bowel Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ramosetron - Drug Profile
ibodutant - Drug Profile
crofelemer - Drug Profile
LX-1031 - Drug Profile
LIBS - Drug Profile
M-0014 - Drug Profile
linaclotide - Drug Profile
linaclotide - Drug Profile
rifaximin - Drug Profile
asimadoline - Drug Profile
asimadoline - Drug Profile
M-0012 - Drug Profile
MDT-006 - Drug Profile
AST-120 - Drug Profile
dextofisopam - Drug Profile
plecanatide - Drug Profile
dexloxiglumide - Drug Profile
solabegron hydrochloride - Drug Profile
larazotide acetate - Drug Profile
TC-6499 - Drug Profile
ALB-137391(a) - Drug Profile
RQ-00202730 - Drug Profile
elobixibat - Drug Profile
PBI-1737 - Drug Profile
eluxadoline - Drug Profile
RQ-00310941 - Drug Profile
DA-6886 - Drug Profile
RDX-5791 - Drug Profile
ONO-2952 - Drug Profile
LX-1033 - Drug Profile
ASP-7147 - Drug Profile
YH-12852 - Drug Profile
(Mosapride + Bacillus subtilis + Streptococcas feacium) - Drug Profile
DSP-6952 - Drug Profile
mexiletine hydrochloride - Drug Profile
Irritable Bowel Syndrome Therapeutics - Drug Profile Updates
Irritable Bowel Syndrome Therapeutics - Discontinued Products
Irritable Bowel Syndrome Therapeutics - Dormant Products
Irritable Bowel Syndrome - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=556319&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

(PRBuzz.com) April 5, 2013 -- Global Markets Direct's, 'Growth Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Growth Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Growth Disorders. Growth Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556364_growth_disorders_pipeline_review_h1_2013.aspx?afid=101
------------------------------------------------------------

Scope

* A snapshot of the global therapeutic scenario for Growth Disorders.
* A review of the Growth Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Growth Disorders pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Growth Disorders.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Growth Disorders pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Growth Disorders Overview
Therapeutics Development
An Overview of Pipeline Products for Growth Disorders
Growth Disorders Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Growth Disorders Therapeutics - Products under Development by Companies
Companies Involved in Growth Disorders Therapeutics Development
Novo Nordisk A/S
Zosano Pharma, Inc.
PROLOR Biotech, Inc.
Biovitrum AB
JCR Pharmaceuticals Co., Ltd.
Asterion Ltd
Physica Pharma
GeneScience Pharmaceuticals Co., Ltd.
Phage Biotechnology Corporation
iBio, Inc.
USV Limited.
Growth Disorders - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PHY-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOD-4023 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bucelipase alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin Long-Acting - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Growth Factors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Growth Hormone ZP Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
xl-020 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Growth Hormone Agonists - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Growth Disorders Therapeutics - Drug Profile Updates
Growth Disorders Therapeutics - Discontinued Products
Growth Disorders Therapeutics - Dormant Products
Growth Disorders - Product Development Milestones
Featured News & Press Releases
Sep 26, 2012: BioMarin Pharma Announces Phase I Results For BMN-111 For Achondroplasia
Sep 10, 2012: Ipsen Pharma Maintains Increlex Supply In US
Feb 16, 2012: BioMarin Initiates Phase I Trial For BMN-111 For Treatment Of Achondroplasia
Jan 03, 2012: BioMarin To Initiate Phase I Trial In BMN-111 For Treatment Of Achondroplasia
Nov 25, 2011: Hanmi Pharma Files With EMA For Orphan Drug Designation Of LAPS-rhGH
Nov 11, 2011: Hanmi Pharma To Maximize Commercial Opportunities Of LAPS-hGH Through EMA's Orphan Drug Designation And Pediatric Investigation Plan
Oct 27, 2011: Hanmi Pharma To Begin Phase II Study Of LAPS-hGH In European Territories
Oct 24, 2011: HanAll BioPharma Initiates Phase I Trial Of Vitatropin
Sep 27, 2011: Biopartners And LG Life Sciences Present Positive Phase III, 24 Months Efficacy And Safety Data For LB03002 Given To Children With Growth Hormone Deficiency
Aug 02, 2011: Swedish Orphan Biovitrum Announces First Patient Enrollment In Kiobrina Phase III Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Growth Disorders, H1 2013
Products under Development for Growth Disorders - Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Novo Nordisk A/S, H1 2013

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=556364&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

(PRBuzz.com) April 5, 2013 -- Global Markets Direct's, 'Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556365_non_muscle_invasive_bladder_cancer_nmibc.aspx?afid=101
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
* A review of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview
An Overview of Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Products under Development by Companies
Companies Involved in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Development
Spectrum Pharmaceuticals, Inc.
Altor BioScience Corporation
Telormedix SA
Viventia Biotechnologies Inc.
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
apaziquone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
apaziquone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TMX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oportuzumab monatox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALT-803 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TD-6989 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TD-3633 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEL-031 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Drug Profile Updates
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Dormant Products
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Product Development Milestones
Featured News & Press Releases
Sep 11, 2012: Cold Genesys Announces Agreement With FDA On Special Protocol Assessment Of Phase II/III Pivotal Trial Of Bladder Cancer Candidate
Apr 18, 2012: Celek Pharma To Present Recent Progress On Anticancer Drug, CEL-031, At NCI's Investor Forum
Apr 05, 2012: Spectrum Announces Results Of Apaziquone Phase III Clinical Trials
Apr 02, 2012: Connaught Strain Of BCG Shows Potential To Treat Non-Muscle-Invasive Bladder Cancer In Phase III Study
Mar 19, 2012: Telormedix's TMX-101 Exhibits High Safety In Phase I/II Trial For Non-Muscle Invasive Bladder Cancer
Jan 19, 2012: OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H1 2013

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=556365&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

(PRBuzz.com) April 5, 2013 -- Global Markets Direct's, 'Pyelonephritis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pyelonephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pyelonephritis. Pyelonephritis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556374_pyelonephritis_pipeline_review_h1_2013.aspx?afid=101
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Pyelonephritis.
* A review of the Pyelonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Pyelonephritis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Pyelonephritis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Pyelonephritis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Report Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pyelonephritis Overview
Therapeutics Development
An Overview of Pipeline Products for Pyelonephritis
Pyelonephritis Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pyelonephritis Therapeutics - Products under Development by Companies
Companies Involved in Pyelonephritis Therapeutics Development
AstraZeneca PLC
Merck & Co., Inc.
Cubist Pharmaceuticals, Inc.
Achaogen Inc.
MerLion Pharmaceuticals Pte Ltd
Pyelonephritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
plazomicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CXA-201 + [levofloxacin] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
finafloxacin Oral - Drug Profile
Product Description
Mechanism of Action
R&D Progress
avibactam + [ceftazidime] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
finafloxacin Intravenous - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-7655 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pyelonephritis Therapeutics - Drug Profile Updates
Pyelonephritis Therapeutics - Discontinued Products
Pyelonephritis Therapeutics - Dormant Products
Pyelonephritis - Product Development Milestones
Featured News & Press Releases
May 15, 2012: Achaogen Provides Update On Phase II Study Of Plazomicin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Pyelonephritis, H1 2013
Products under Development for Pyelonephritis - Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
AstraZeneca PLC, H1 2013
Merck & Co., Inc., H1 2013
Cubist Pharmaceuticals, Inc., H1 2013
Achaogen Inc., H1 2013
MerLion Pharmaceuticals Pte Ltd, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Pyelonephritis Therapeutics - Drug Profile Updates
Pyelonephritis Therapeutics - Discontinued Products
Pyelonephritis Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Pyelonephritis, H1 2013
Products under Development for Pyelonephritis - Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Forecasted to Return to 2012 Levels Again by 2017

Scottsdale, AZ, (PRBuzz.com) April 5, 2013 -- Multimedia Research Group, Inc. (MRG), the market leader in the Video and Media ecosystem for more than 20 years, has released The North American Cable TV Market: Subscriber Losses Continue, But Begin to Moderate.

The cable TV market in North America continues to face challenges.  Increasing competition in the pay-TV industry, as well as a stubbornly flat macroeconomic climate, has resulted in another year of subscriber losses.  2012 marked the seventh consecutive year that cable TV subscriber households decreased in North America. 

However, it should be noted that there appears to be some positive news on the horizon.  For the past several calendar quarters, the pace of cable subscriber losses has been slowing.  Senior Analyst Mike Paxton explains further "While we expect 2013 to be another year marked by decreasing North American cable TV households, MRG believes that the total number of households lost will be much lower than in 2012. Improving macroeconomic conditions, coupled with the development of new video service packages and features, should reduce the loss of subscribers in 2013 to less than 1 million."

Key findings for this research include:

• By 2015, we are projecting that cable TV video service subscribers will actually experience growth, albeit at a very modest level.
• By 2017, North American cable TV video service subscribers are projected to again exceed 64 million, returning nearly to the level they reached at year-end 2012.
• Among North American cable TV operators, Comcast continues to be the largest with over 21.9 million video service subscribers.

This report provides an update on the North American cable TV market. Specifically, it looks at the size of the market by providing the current number of cable TV subscribers and a subscriber forecast through 2017. It also provides a detailed list of the "Top 95" cable TV operators in North America. This list ranks the operators by video service subscribers and provides background data and contact information for each operator.

The deliverable is comprised of a PDF and an Excel spreadsheet.

About Multimedia Research Group, Inc.

Founded in 1990, Multimedia Research Group, Inc. is headquartered in Scottsdale, AZ with offices in Washington, Chicago, and the United Kingdom. MRG provides video and media market analytics and industry intelligence of new technologies and strategic consulting services for its clients that include Alcatel-Lucent, Broadpeak, Deutsche Telekom, Edgeware, Ericsson, Motorola, NEC, Orange/France Telecom, Verimatrix, ZTE and many more.  At the core of MRG's value proposition is an acute focus on outperforming growth targets, identifying and mitigating risks, strategically assessing new market opportunities and identifying potentially disruptive technologies.

For more information, visit www.mrgco.com, or for a complimentary sample of this report, please contact Elaine Potter at elaine@mrgco.com.

(PRBuzz.com) April 5, 2013 -- See us in Las Vegas, April 8th - 11th 2013. Booth SL3305

During live sporting events, broadcasters go to great lengths to enrich the viewing experience with slo-mo replays, telestration, and in-game graphics to explain controversial and key plays. While these effects often require placing costly or complex broadcast cameras and calibration devices around the stadium or hiring specialized services, Viz Libero gives viewers this sameinsight by processing existing video.

Virtual SloMo

At the 2013 NAB Show, Vizrt will present the new features and workflow improvements in Viz Libero 5.5, its 3D virtual sports enhancement and analysis system. Viz Libero 5.5 now offers Virtual SloMo, which uses an advanced image-based algorithm to generate ultra-slow motion (up to 1500 fps) footage rather than relying on high-speed camera systems. Virtual SloMo and other Viz Libero 3D replay tools can be used on any live camera image or remote video feed.

Grass Valley K2 Summit / Dyno Integration

Viz Libero 5.5 adds integration with the Grass Valley K2 Summit media server and K2 Dyno replay system, both of which are widely used in studio and remote sports production environments. It also improves integration with the entire Vizrt product family, including Viz Engine 3.6 for real-time 3D graphics and video compositing. This enables customized graphics to be rendered through a Viz Engine for greater creative control, inserting virtual presenters into the analysis clips, and the ability to present analysis scenes on interactive touchscreens.

New support for Motorsports, tennis, cricket and other sports

Viz Libero 5.5 adds in-game 3D virtual sports toolsets geared to motorsports, tennis, cricket, field hockey as well as Australian football. The system already supports many others, such as football, American football, ice hockey, baseball, basketball, and volleyball.

New and improved effects

Viz Libero has been enhanced by many new in-game effects which help viewers to understand the different sports. These features include, among others, height measurement, ball impact, blocking wall, player grow, or zone focus. Many of the Viz Libero features, such as player marker, labels or offside and 3D wall, now have a customization interface within Viz Libero.

The Virtual Run that animates player movement, one of the big innovations in 2012, has received improvements. Besides simpler handling of the Virtual Run, new elements like a strobe effect have been added.

An existing feature, the 3D Ball Track, can now be created with only one camera feed. This makes the feature faster, and more readily available, even for studio productions with only one multilateral camera signal.

Improved workflow tools

File-based workflows, including video file ingest and output, are also improved for simplified studio integration. Viz Libero 5.5 expands supported output formats to include: Apple RLE/MOV, DNxHD/MOV, and DVC Pro 100/MXF.

The new version also adds a visual editor timeline, which accelerates post-editing of analysis clips. The timeline provides a graphical overview of the playlist including all recorded annotations and tracks so operators can edit and synchronize any graphics, 3D flights, or other elements.

With these latest 3D sports analysis features, tools, and workflow improvements, Viz Libero 5.5 enables broadcasters to enhance their live sports shows with greater creative latitude and cost-efficiency.

About Vizrt:

Vizrt provides real-time 3D graphics and asset management tools for the broadcast industry - from award-winning animations & maps to online publishing tools. Vizrt's products are used by the world's leading broadcasters and publishing houses, including: CNN, CBS, Fox, the BBC, BSkyB, ITN, ZDF, Star TV, Network 18, TV Today, CCTV, NHK, The Globe and Mail, Times Online, The Telegraph, and Welt Online. Furthermore, many world-class production houses and corporate institutions such as the Stock Exchanges in New York and London use Vizrt systems.

Vizrt is a public company traded on the Oslo Main List: VIZ, ISIN: IL0010838154. For further information please refer to www.vizrt.com

Martin Burkhalter / CEO / +41 22 365 75 01 / MBurkhalter@vizrt.com
Tomer Wald / CFO / +47 5351 8040 / TWald@vizrt.com
Håvard Myklebust / EVP Products & Marketing / +4791845602 / HMyklebust@vizrt.com

East Whittier Glass and Mirror is currently celebrating 49 years of business. They started their business in 1864 and have satisfied many customers, both large and small. 

Whittier, CA USA, (PRBuzz.com) April 5, 2013 -- East Whittier Glass and Mirror has announced that they are celebrating 49 years of business. They originally started their business back in 1964 and today, they are still going strong. They have satisfied thousands of customers, both residential and commercial. They didn't get this far by just sitting there - they know what hard work is all about and don't mind going the extra mile to make one of their customers happy.

On their website, they state: "One of our greatest strengths is our history." Being in operation for 49 years definitely shows that they are trustworthy and that really captures people's attention. The company is family owned and operated. Their staff is professional and can assist individuals in all of their glass needs. Their prices are also affordable, which is why so many customers choose them.

They are currently serving the following areas:

• Los Angeles
• Orange
• San Bernardino

They work in the following areas:

• Window replacement/installation
• Shower restoration
• Patio and balcony work
• Mirrors
• Custom tabletops

They work with both commercial and residential customers.

The Whittier window replacement installation specialists realize just how important curb appeal is, which is why they repair or replace windows with professionalism. When a window is cracked, it can run up an energy bill, so it is important to get the window repaired right away.

East Whittier Glass & mirror has been in operation for 49 years, because of the quality materials, services and products they offer. Some individuals may need specific shower door needs, which is where Whittier all glass showers and Whittier Frameless Shower Doors comes into play. For 49 years, they have been creating shower designs that complement the home.

About East Whittier Glass and Mirror

East Whittier Glass and Mirror, a family owned and operated business, has been in operation for 49 years - they first started their business back in 1964. They handle shower restoration, window installation/repair, custom tabletops, mirror installation and patio/balcony work.

Company Name : East Whittier Glass and Mirror
Company Locations (City, State, Country): Whittier, CA USA
Company Contact : Shaun Toews

It is obvious that RottenMonkey has captured the attention of readers, because RottenMonkey.com has accumulated over 25,000 readers in less than 6 months. 

Las Vegas, Nevada, (PRBuzz.com) April 5, 2013 -- RottenMonkey.com, an alternative news site, with a catchy logo of a monkey holding a knife, announced that they have accumulated over 25,000 readers in less than 6 months. With that many readers, it is obvious that they are doing something right - people seem to enjoy the way the news is presented on the site. The news site was officially launched on October 1, 2012 and already has thousands of readers.

As stated on RottenMonkey.com's FaceBook fan page: "We chop up the news and feed you what is real." They cover popular news in a way that makes people want to read it - they do not "sugar-coat" anything. This is news that has been written by REAL people. The writers are paid through a revenue sharing system - not by RottenMonkey.com, so the opinions on the site are of writers and not the site owners and operators.

Categories on RottenMonkey include:

• Politics
• Entertainment
• Justice
• Economy
• Tech
• Living
• Health
• Sports
• Travel
• Opinion
• Global
• U.S

While there are many sections on the site that people enjoy reading, the most popular sections as of today are the Entertainment and Political News.

There are many "catchy" headlines posted daily on the site. The latest ones include: "What Did 'Entertainment Tonight' Get Wrong This Week," "Hollywood Bows to Our Chinese Overlords by Altering Blockbusters," "Latest Mets Mishap: Johan Santana's Career is Probably Over" and "Morning Talk Show Shuffle: Walters Retiring ... Lauer Leaving?" The news articles are written so that any individual will be able to read them and understand them.

Readers can also follow "RottenMonkey" on FaceBook in order to get updates when new news articles have been posted to the site.

About RottenMonkey.Com

RottenMonkey.com is an alternative news site. They chop up the news and feed their readers what is real. They cover popular news and post to their site on a daily basis. They gained over 26,000 readers in less than 6 months.

Company Contact : Kevin Smothers
Company Email : vegaskev@hotmail.com

Company Phone : +1.7022046487

Aliso Viejo, California (PRBuzz.com) April 5, 2013 -- Online divorce forms service company, MyDivorceDocuments.com, found an interesting new divorce statistic in their end of the month report. It was discovered that divorce filings dropped 39% in the days before the Easter holiday on March 31st. But after the Easter holiday, the percentage of people filing for divorce returned to normal.

Statisticians have noted links between various holidays and fluctuations in the divorce rate, but Easter has not been considered a holiday that has any bearing on the divorce rate. The usual holidays that appear to affect the divorce rate include Christmas, New Year's, and Valentine's Day.

Upon approaching these holidays, the divorce rate suddenly drops. After the holiday passes, the rate of people filing for divorce spikes for a week or so. However, the time period between January and March is known as divorce season, which includes both the New Year holiday and Valentine's Day.

It is speculated that holidays, which bring lots of family interaction, intensifies the emotional distress of unhappily married people. The holidays then become the straw that broke the camel's back.

MyDivorceDocuments.com is an online divorce forms service company that operates in all 50 U.S. states. MyDivorceDocuments.com provides two services for clients seeking an uncontested divorce:

The Do-It-Yourself service provides clients with all the divorce paperwork for their specific state and county and a detailed instruction guide.

The Premiere service compiles and completes the divorce forms for the client, and provides a guide to filing the forms.

For more information about divorce new, visit the MyDivorceDocuments.com blog; for more information about MyDivorceDocuments.com's services, visit www.MyDivorceDocuments.com.

####

MyDivorceDocuments.com

92 Argonaut, Suite 200
Aliso Viejo, CA 92656

(949) 630-0380

info@mcclainconcepts.com

(PRBuzz.com) April 5, 2013 -- iHomefinder is pleased to announce that Scott Jensen of Evergreen Real Estate has become a new Optima Express client. Scott is the founder, owner and broker-in-charge of Evergreen Real Estate. This brokerage serves the Charlotte, North Carolina area. Scott is one of the top real estate agents in the Charlotte area. He has a reputation for helping buyers find the best deals and helping sellers get their home sold for top dollar. With iHomefinder Optima Express, Scott and his team offer website visitors a fast, accurate property search experience. Enhanced Property Details Pages, Facebook Search and Featured Apps, and Branded Email Updates are just a few of the ways that Scott can deliver value and stay connected with prospects and clients online. iHomefinder has been an industry leader in secure MLS property search and compliant MLS data management for over fourteen years.

With Enhanced Property Details Pages, each listing has up to twenty-five large photos and displays property data in an easy-to-read format that contains current and compliant MLS data. Visitors to these pages also have access to property and area related information from Walk Score, Google Maps, GreatSchools and a Mortgage Calculator. They can easily share their favorite listings with family and friends through social media. Sharing is quick and easy. The social media sharing creates valuable backlinks to an agent or broker's website. The Facebook Search and Featured Apps allows agents and brokers to add property search and their own listings to their Facebook Business page. The Facebook App helps drive more traffic back to the realtor's website.

Optima Express provides branded Email Alerts. On a daily basis, these branded emails deliver valuable property information that matches a subscriber's saved search criteria. This feature helps realtors like Scott stay in touch with clients and prospects easily. Emails are also automatically sent when there are changes on in the status or price of a property. The emails are all branded with the realtor's logo. Email Alerts are a powerful tool for turning website visitors into prospects, and prospects into clients.

More and more, people are conducting their home search online. Scott is able to serve this kind of real estate consumer with Optima Express. Home shoppers will be able to search for new properties, access saved searches, view open houses and contact Scott anytime, either from their home computer or from any mobile device with a browser. With Optima Express, Scott is both delivering an exceptional online experience to his clients and potential client, and making an important investment in his online presence.

###

About iHomefinder, Inc.

iHomefinder is a leading national provider of real estate search technology and websites. Using the Internet Data eXchange (IDX) standard, iHomefinder securely powers hosted property search and lead capture in thousands of real estate websites. We partner with a wide array of web designers to integrate our technology in real estate websites. We also maintain trusted relationships with hundreds of MLSs across the U.S. to provide licensed, accurate, and timely listing data. The company maintains a long-standing reputation for strict compliance with the local rules of each MLS.

In addition to serving real estate professionals, iHomefinder provides technical compliance and consulting services to innovative Internet marketing firms who require licensed access to national real estate listing data.

Established in 1997, iHomefinder is privately held and headquartered in the San Francisco Bay Area.

Press contact: Glenn Flinchbaugh, glenn@ihomefinder.com

Tucson, AZ (PRBuzz.com) April 5, 2013 -- Tucson, AZ based Berwick Insurance Group L.L.C. has created a web based resource for anyone considering a career in the insurance industry. The website, www.insurancecareer.com is designed to provide a wide range of information related all types of Insurance careers and other industry information. The site also includes a live insurance jobs feed that lists opportunities in their geographic area.

Founding partner David Berwick explains "Berwick Insurance Group created this resource as a way to help individuals that are interested in insurance careers not only find information about the different types of opportunities in our industry, but also provide valuable information like licensing requirements and pay scale"

The Insurance Career website contains comprehensive details about all types of insurance as well as a "pros and cons" section that lists some of the positive and negative aspects of each insurance career choice.

"The site is constantly being updated with the most recent industry data and has already been visited by thousands of information seekers. We put a lot of work into this project and are pleased that it's becoming a valuable resource for so many" added Mr. Berwick.
.
Media: For interviews with Berwick Insurance Group, please call the contact listed at the bottom of this press release.

About Berwick Insurance Group

Berwick Insurance Group is a national independent marketing organization contracted to recruit agents to sell a variety of insurance products. We specialize in the senior products industry, which includes Final Expense and Medicare Advantage plans, Medicare Supplements and more.

David Berwick
Berwick Insurance Group L.L.C.
4576 E Camp Lowell Dr.
Tucson, AZ 85712
520-745-2300
http://www.insurancecareer.com/

Astoria, NY (PRBuzz.com) April 5, 2013 -- 4OVER4.COM is offering premium sales sheets printing services at the lowest rates available anywhere with its special discounts for businesses. Top NY business printing services provider 4OVER4.COM provides leading digital and offset printing services including large format printing, sticker printing, fabric banners printing, custom decals printing, custom labels printing and other premium printing services for businesses.

Leading New York web printing provider 4OVER4.COM has launched special discounts on sales sheets printing for businesses. The discounts are bundled with an all-new sales sheets printing service featuring new low 50 minimums, optional hi-gloss UV, between 3 to 8 sheets and a selection of premium high quality papers - all for the lowest prices available anywhere. 4OVER4.COM stands ahead of the competition with the highest quality printing materials and a wide range of best-in-class professional printing and finishing options.

4OVER4.COM customers stand to enjoy new premium high quality papers including 14pt gloss cover, 16pt gloss cover, 100# gloss text, 70# uncoated text, 14pt uncoated cover (30% recycled), 13pt uncoated cover (100% recycled), 15pt synthetic plastic, 6mil synthetic plastic and 14pt white linen. 4OVER4.COM now also provides its customers with sales sheets in sizes of 8.5" x 11" and 4OVER4.COM customers can get between 50 and 100,000 prints per order.

"Sales sheets combine useful information on a product or service with powerful graphics to create an effective tool for promotion as well as reference," says 4OVER4.COM Principal Taso Panagiotopoulos.

For more information about staggered-cut sales sheets or for any updates or inquiries, please visit 4over4.com/printing/Staggered-Cut-Sales-Sheets, email support@4over4.com or call the 4OVER4.COM customer care line on 1-718-932-2700.

About 4OVER4.COM

Online printing company 4OVER4.COM, an NYC printing firm, is a green printing company that serves tens of thousands of clients nationally and whose printing New York facility began operations in 1999.4OVER4.COM provides unmatched technical and customer support and instant online pricing and ordering for full color printing services since 1999, 4OVER4.COM has offered free expert file review and free online proofs without any obligation to purchase. As a green printing company, we are strongly oriented towards sustainable environmental renewal, and we are happy to lead the way with environmentally and socially responsible printing practices and projects among national as well as New York Printers.

(PRBuzz.com) April 5, 2013 -- The Hon. Legrome D. Davis of the United States District Court for the Eastern District of Pennsylvania has ruled that a homeowner stated viable claims against Bank of America, N.A. and Walled Lake Credit Bureau, LLC for violations of the Fair Debt Collection Practices Act, 15 U.S.C. § 1692 et seq., and the Unfair Trade Practices and Consumer Protection Law, 73 Pa.C.S. § 201.1 et seq. As detailed in the class action complaint, the bank and its affiliated debt collector repeatedly and falsely told consumers that they missed mortgage payments and wrongfully threatened to foreclose on their homes.

The plaintiff in this putative class action is represented Kalikhman & Rayz, LLC - a legal practice focused on serving individuals and businesses in need of expert advice in southeastern Pennsylvania and the neighboring State of New Jersey, as well as Faruqi & Faruqi, LLP - a leading national class action firm headquartered in New York.

The law firm of Kalikhman & Rayz, LLC is a legal practice focused on serving individuals and businesses in need of expert advice in southeastern Pennsylvania and the neighboring State of New Jersey. Dedicated to producing results, we pride ourselves on listening to our clients and providing creative legal guidance consistent with their goals and needs.

Contact:
Eric Rayz, Esquire
erayz@kalraylaw.com
Kalikhman & Rayz, LLC
1051 County Line Road, Suite "A"
Huntingdon Valley, PA 19006
United States of America
Phone: (215) 364-5030
Fax: (215) 364-5029
http://www.kalraylaw.com/

###

(PRBuzz.com) April 5, 2013 -- QualityStocks would like to highlight Enphase Energy (NASDAQ: ENPH). The company brings a system-based, high-tech approach to solar energy, leveraging expertise in semiconductor integration, power electronics and networking technologies to continually advance the performance, intelligence, and reliability of solar energy systems. Enphase's vision is to make solar simple and energy smart so everyone is empowered to create a zero energy footprint for themselves, their home, and their business.

In the company's recent news,

Enphase Energy announced that its relationship with Vivint Solar has been renewed for 2013 regarding Enphase's inverter solution. Vivint Solar is an affiliate of Vivint Inc., a leading provider of home technology services in North America.

"We are delighted to continue building off our powerful strategic relationship with Vivint Solar. For over a year-and-a-half, our advanced inverter technology, coupled with Vivint Solar's unique go-to-market, has helped accelerate them toward their goal of becoming the top U.S. installer of residential rooftop solar systems," said Jeff Loebbaka, senior vice president of worldwide sales and field operations of Enphase Energy.

Vivint Solar saves customers money on energy through a power purchase agreement (PPA). A PPA stipulates that customers will purchase electricity generated by a solar photovoltaic system installed on their home, at rates that are typically cheaper than their local utility. In exchange for this opportunity to use cheaper electricity, Vivint Solar designs, installs, operates, and maintains the system without any additional cost to customers. This business model gives homeowners access to cheap, renewable solar energy without the large, upfront investment.

"We are focused on nationwide expansion of our affordable solar offering, and we adopted Enphase early on because of the value their inverter solution delivers," said Dan Rock, vice president of installs of Vivint Solar. "Enphase inverters provide flexibility to Vivint Solar's installation crews and provide Vivint Solar's customers with more efficient solar energy systems, resulting in enhanced savings to our customers."

The Enphase Microinverter System, the primary product in the collaboration between Enphase and Vivint, delivers a revolutionary new approach to the installation, operation, and maintenance of photovoltaic systems. Enphase Microinverters, the Envoy Communications Gateway, and Enlighten web-based monitoring and analysis software collaborate to provide increased energy harvest and cutting-edge solar system intelligence. Over the life of the company, Enphase has shipped more than 3 million microinverters and is selling into ten countries across Europe, North America, and Asia Pacific.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Contact

Senior Editor
QualityStocks
480-374-1336
Editor@QualityStocks.net

(PRBuzz.com) April 5, 2013 -- Operation Kindness, the oldest and largest no-kill shelter in North Texas, is asking the public for its help to stop animal abuse.

"Animal cruelty is a widespread problem, but it's something anyone can help fight. If you know the signs of animal abuse and are willing to do what you can to stop it, we can eliminate this problem and save a lot of lives," says Nikki Walker, development director of Operation Kindness.

Throughout April, Prevention of Cruelty to Animals Month, Operation Kindness will offer $25 off of regular adoption fees, provided the adopter signs a pledge against the cruelty of animals. The pledge is designed to educate people on animal cruelty in hopes of helping them learn to recognize the major and subtle signs of animal abuse and eliminate those behaviors in themselves and in others.

"A lot of people don't realize that animal abuse isn't just the obvious things. Neglect is a form of animal abuse too, and it's a lot more common - things like not giving your animals regular veterinary care or keeping them outside in the elements without proper shelter," notes Julie Goff, special events manager of Operation Kindness. "We're asking everyone who adopts during the month of April to sign the pledge, and we're encouraging the public to sign too. Awareness and education are the keys to eliminating animal abuse."

People can sign the pledge at www.OperationKindness.org; at the shelter - located at 3201 Earhart Drive in Carrollton, TX 75006; or at any of the following community outreach and adoption events:
• April 7, 1 p.m. to 5 p.m. The Dog Bowl at Fair Park in Dallas
• April 13, 4 p.m. to 10 p.m. CLASP Crawfish Boil at Vitruvian Park in Addison
• April 20, 12 p.m. to 4 p.m. Whole Foods Plano
• April 27, 11 a.m. to 3 p.m. FETCH! At Ebby Halliday (NW Highway and Preston)
• April 30, 12 p.m. to 4 p.m. PetSmart in West Plano

Anyone who signs the pledge can pick up a free Operation Kindness magnet, which will be available at community outreach and adoption events and at the shelter, while supplies last.

In addition to the pledge, Operation Kindness will post educational resources on Facebook and Twitter that identify common signs of animal abuse and solutions for stopping it.

"Talk to your friends, neighbors and co-workers about their animals. Educate them about neglect, and pledge to act when you suspect abuse," adds Walker. "Animal abuse stops with you. If something doesn't look or sound right, call animal services or your local city shelter. Most city shelters have a cruelty director that can help you. Also, you can call the police because animal abuse is a crime."

Founded in 1976, Operation Kindness is the oldest and largest no-kill shelter in North Texas. Its mission is to care for homeless cats and dogs in a no-kill environment until each is adopted into responsible homes and to advocate humane values and behavior. On a daily basis, Operation Kindness cares for an average of 300 animals at the shelter, with more than 100 animals in foster homes. Operation Kindness has saved more than 75,000 animals since its inception, and it assists more than 3,000 dogs and cats each year. Learn more about Operation Kindness by calling 972-418-PAWS or by visiting http://www.operationkindness.org, https://twitter.com/OpKindness or www.facebook.com/pages/Operation-Kindness/30251945822).
###

Contact:
Jo Trizila
TrizCom Inc.
jo@Trizcom.com
Office: 972-247-1369
Cell: 214-232-0078

From: Skizzleville Inc., 25876 The Old Road, S. 155, Santa Clarita, CA 91381, USA
(www.skizzleville.com)

Contact: Josie Snyder, CEO, 661-794-7594, Skizzleville@yahoo.com

FOR IMMEDIATE RELEASE

Not Just Another Online Social Network...Skizzleville Strives to Create a Difference!

(PRBuzz.com) April 5, 2013 -- Skizzleville is a new, social network that caters for a new crowd of preteens and teens. Rising privacy concerns are becoming present with the likes of many online sites today, it's not surprising that children are fast become the lure of sexual predators, identity theft, bullying and so much more...

With the help of non-profit organization Kids Net Worldwide and Skizzleville will look at ways in which we can overcome this.

On the 23rd of March, Skizzleville Inc. launched their first live event, sponsored by Kids Net Worldwide and many Santa Clarita Businesses, which may be seen in their online virtual movie theater.

This revolutionary new platform is devoted to education through entertainment, motivation, inspiration, creating awareness and creating entrepreneurs from our youth has added yet another aspect giving pre-teens and teens the ability to showcase their talents worldwide, through their new monthly online Magazine sponsored by Kids Net Worldwide, highlighting some of the chosen submissions to their network. The project in order to sustain itself requests a mere $24.00 donation through Kids Net Worldwide which is tax deductible, for this online magazine throughout the year, however 40% of these proceeds will go towards providing scholarships to participants and members. This will all be overseen by Oscar Dominguez of Union Bank Santa Clarita, Financial Partner assisting with the online scholarship program.

Josie Snyder Ceo of Skizzleville said, "We need to create change, and we can make the difference, it's up to all of us to understand what's going on in our ever driven technology and what we need to do as parents to guide our future generations."

This new social platform was designed with help from Snyder's own two young men, who play a major role as part of the animated characters throughout the site. A part from being a strong business woman, as a mother she cares about what's happening in our education system, and values privacy as well as education but also understands entrepreneurial skills and talent and wanted to offer more than just an online game room, or chat room, and therefore created this multi-level platform where our youth have the opportunity to learn, create, protect, showcase, and inspire others. Snyder closes with, "Isn't it time to create a unique experience where we can help further our youth's goals and inspirations, they have the ability to be anything they want, let's help them, it's time!"

Make sure to catch Josie's very first interview with Ron Stark's show The Voice, airing on KVCR (PBS) airing April 8th and 13th.

If you haven't checked out this site, make sure you do at www.skizzleville.com.

Dallas, TX, (PRBuzz.com) April 5, 2013 -- Book2Park got featured on SkilledPilots.com which is an aviation directory where aviation businesses can list their business for free and get massive online exposure. As of February of 2013 their listings are also available on their iPhone and Android app.

Book2Park is a company dedicated to providing secure airport & seaport parking nationwide specializing in saving customers money and time. They share their customers' belief: There is no reason to overpay for parking when travelling anymore!

They provide a secure, guaranteed parking space near a destination airport or seaport by working with brand hotels. Via their website it is possible to book a guaranteed parking spot within minutes. Simply drop off your vehicle at one of their approved facilities and ride the complimentary shuttle to a departing destination with peace of mind. No more overpaying and any vehicle will be in a safe location until the customer returns.

Anna Infante VP of Sales & Marketing of the company said: "It is rewarding to hear the great feedback we get from our customers! Many people still haven't experienced this new concept and after they try it, they want to keep using our services! We really care for our customers and our main goal here at Book2park.com is to provide them with 100% customer service and the best experience they will get in the market!"

You can find more information about Book2Park @

https://www.skilledpilots.com/listing/book2park-com/

"Our goal is to give massive exposure to the aviation businesses who post their listings on our aviation directory at SkilledPilots.com. We have already been noticed and mentioned by 85+ highest ranked US media outlets such as ABC News, Boston Globe, Miami Herald, The Columbus Dispatch, The Telegraph, San Francisco Chronicle, Sign On San Diego and many more", said Director of Digital Marketing, Jason parker.

About SkilledPilots.com

SkilledPilots.com is an aviation directory where aviation businesses can list their business for free and a fast growing community of skilled pilots and aviation enthusiasts. It's our goal to get the most exposure possible for the aviation businesses listed on our aviation directory, iPhone and Android app.

For all media inquiries, please contact:

Jason Parker
Direct 1-888-300-6849
jason@skilledpilots.com